Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a $40bn valuation by 2040.

However, technical hurdles in the field remain. This month's cover feature analyses the key challenges and reflects on the way forward for ADC research and development.

Also in this issue, we look at the makeup of the next wave of obesity drugs, US pharma Insmed's new UK site, and how the new US-EU trade deal on tariffs signifies the end of pharma’s geopolitical immunity.

Don't miss our exclusive interview with Dr. Mariana Socal on the impact of Trump's tariffs on pharma.

Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

"Magazine: Big biopharma take on the ADC challenge" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.